Clinical Trials Logo

Anti-MAG Neuropathy clinical trials

View clinical trials related to Anti-MAG Neuropathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT05136976 Recruiting - Anti-MAG Neuropathy Clinical Trials

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

THERAMAG
Start date: June 29, 2023
Phase: Phase 3
Study type: Interventional

Anti-MAG neuropathy is a progressively disabling orphan rare disorder due to a monoclonal immunoglobulin M(IgM) gammopathy displaying reactivity toward MAG, a glycoprotein of the peripheral nervous system. Its prevalence is around 1/100000 and to date, no treatment has proven efficacy in this disease, including rituximab in 2 Randomized Controlled Trails(RCTs).

NCT ID: NCT04568174 Terminated - Anti-MAG Neuropathy Clinical Trials

First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy

Start date: November 17, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, the new drug called PPSGG (PN-1007) will be tested. Preliminary studies conducted in animals suggest PPSGG (PN-1007) might be a good treatment for reducing levels of anti-MAG antibodies in patients with anti-MAG neuropathy. This is the first research of PPSGG (PN-1007) in people and its main purpose is to test its safety and acceptability in patients. In this study it will be examined how the drug is changed by and removed from the body and checked for signs that the drug may be truly effective against anti-MAG neuropathy. PPSGG (PN-1007) will be tested at several different doses.

NCT ID: NCT03397303 Not yet recruiting - Clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy

Quantification of Nerve Stiffness in Neuropathies

Nerf_SSI
Start date: April 2018
Phase: N/A
Study type: Interventional

This project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . Stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. Patients will be compared with age-matched controls.

NCT ID: NCT02967679 Completed - Clinical trials for Peripheral Neuropathy

SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

Start date: December 5, 2016
Phase: Phase 2
Study type: Interventional

The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.